Direct-to-Consumer Stem Cell Marketing and Regulatory Responses
Author:
Open Access
- 9 August 2013
- journal article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 2 (9) , 638-640
Abstract
There is a large, poorly regulated international market of putative stem cell products, including transplants of processed autologous stem cells from various tissues, cell processing devices, cosmetics, and nutritional supplements. Despite the absence of rigorous scientific research in the form of randomized clinical trials to support the routine use of such products, the market appears to be growing and diversifying. Very few stem cell biologics have passed regulatory scrutiny, and authorities in many countries, including the United States, have begun to step up their enforcement activities to protect patients and the integrity of health care markets.Keywords
This publication has 8 references indexed in Scilit:
- Preventive therapyNature, 2013
- Stem cells in Texas: Cowboy cultureNature, 2013
- Texas Medical Board Approves Rules for Controversial TreatmentScience, 2012
- ASAPS/ASPS Position Statement on Stem Cells and Fat GraftingPlastic and Reconstructive Surgery, 2012
- Stem Cell Stratagems in Alternative MedicineRegenerative Medicine, 2011
- Stem Cell Tourism and Doctors' Duties to Minors—A View From CanadaThe American Journal of Bioethics, 2010
- Science, Politics, and the Regulation of Dietary Supplements: It's Time to Repeal DSHEAAmerican Journal of Law & Medicine, 2005
- It's only skin deep: FDA regulation of skin care cosmetics claims.1999